{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T13:32:07Z","timestamp":1772890327417,"version":"3.50.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.ygyno.2020.09.013","type":"journal-article","created":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T00:52:53Z","timestamp":1601081573000},"page":"721-731","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["An olaparib window-of-opportunity trial in patients with early-stage endometrial carcinoma: POLEN study"],"prefix":"10.1016","volume":"159","author":[{"given":"Ignacio","family":"Romero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Jes\u00fas","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Medina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Matias-Guiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Santacana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan-Antonio","family":"Schoenenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva Maria","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas","family":"Minig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pluvio","family":"Coronado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Fernando","family":"Cueva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lourdes","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Malfettone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Sampayo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Llombart-Cussac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s","family":"Poveda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2020.09.013_bb0005","series-title":"Global Cancer Observatory: Cancer Today","author":"Ferlay","year":"2018"},{"key":"10.1016\/j.ygyno.2020.09.013_bb0010","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2020.09.013_bb0015","first-page":"228","article-title":"A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses","volume":"81","author":"Lax","year":"1997","journal-title":"Verh. Dtsch. Ges. Pathol."},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2020.09.013_bb0020","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1097\/PGP.0000000000000518","article-title":"Endometrial carcinoma diagnosis: use of FIGO grading and genomic subcategories in clinical practice: recommendations of the International Society of Gynecological Pathologists","volume":"38","author":"Soslow","year":"2019","journal-title":"Int. J. Gynecol. Pathol."},{"key":"10.1016\/j.ygyno.2020.09.013_bb0025","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/GCO.0000000000000338","article-title":"Treatment strategies for endometrial cancer: current practice and perspective","volume":"29","author":"Lee","year":"2017","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2020.09.013_bb0030","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/nature08467","article-title":"The DNA-damage response in human biology and disease","volume":"461","author":"Jackson","year":"2009","journal-title":"Nature."},{"key":"10.1016\/j.ygyno.2020.09.013_bb0035","doi-asserted-by":"crossref","first-page":"7303","DOI":"10.1073\/pnas.94.14.7303","article-title":"Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells","volume":"94","author":"de Murcia","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2020.09.013_bb0040","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ijrobp.2003.09.053","article-title":"PARP-1, PARP-2, and the cellular response to low doses of ionizing radiation","volume":"58","author":"Chalmers","year":"2004","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ygyno.2020.09.013_bb0045","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature."},{"key":"10.1016\/j.ygyno.2020.09.013_bb0050","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1200\/JCO.2008.16.0812","article-title":"A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair","volume":"26","author":"Ashworth","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.013_bb0055","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2020.09.013_bb0060","doi-asserted-by":"crossref","first-page":"7491","DOI":"10.1073\/pnas.0914242107","article-title":"Nuclear phosphoinositide 3-kinase beta controls double-strand break DNA repair","volume":"107","author":"Kumar","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2020.09.013_bb0065","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1158\/2159-8290.CD-11-0348","article-title":"PI3K inhibition impairs BRCA1\/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition","volume":"2","author":"Ibrahim","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ygyno.2020.09.013_bb0070","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/path.4056","article-title":"Use of mutation profiles to refine the classification of endometrial carcinomas","volume":"228","author":"McConechy","year":"2012","journal-title":"J. Pathol."},{"key":"10.1016\/j.ygyno.2020.09.013_bb0075","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001538","article-title":"PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors","volume":"2","author":"Dedes","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ygyno.2020.09.013_bb0080","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nature."},{"key":"10.1016\/j.ygyno.2020.09.013_bb0085","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/1471-2407-14-179","article-title":"Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells","volume":"14","author":"Miyasaka","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ygyno.2020.09.013_bb0090","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nrclinonc.2011.42","article-title":"Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer","volume":"8","author":"Forster","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.013_bb0095","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ygyno.2018.05.028","article-title":"Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor","volume":"150","author":"Gockley","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.013_bb0100","series-title":"Exploratory IND Studies. Guidance for Industry, Investigators, and Reviewers","author":"FDA","year":"2006"},{"key":"10.1016\/j.ygyno.2020.09.013_bb0105","doi-asserted-by":"crossref","DOI":"10.1097\/IGC.0000000000000715","article-title":"Biological effects of temsirolimus on the mTOR pathway in endometrial carcinoma: a pharmacodynamic phase II study","author":"Santacana","year":"2016","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2020.09.013_bb0110","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/01.pgp.0000163849.37129.d4","article-title":"Survivin expression in endometrial carcinoma: a tissue microarray study with correlation with PTEN and STAT-3","volume":"24","author":"Pallares","year":"2005","journal-title":"Int. J. Gynecol. Pathol."},{"key":"10.1016\/j.ygyno.2020.09.013_bb0115","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/labinvest.3700286","article-title":"FLIP is frequently expressed in endometrial carcinoma and has a role in resistance to TRAIL-induced apoptosis","volume":"85","author":"Dolcet","year":"2005","journal-title":"Lab. Investig."},{"key":"10.1016\/j.ygyno.2020.09.013_bb0120","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.humpath.2006.05.007","article-title":"PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations","volume":"37","author":"Velasco","year":"2006","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ygyno.2020.09.013_bb0125","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/sim.3840","article-title":"The statistics of phase 0 trials","volume":"29","author":"Rubinstein","year":"2010","journal-title":"Stat. Med."},{"key":"10.1016\/j.ygyno.2020.09.013_bb0130","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/sim.721","article-title":"Sample size tables for exact single-stage phase II designs","volume":"20","author":"A\u2019Hern","year":"2001","journal-title":"Stat. Med."},{"key":"10.1016\/j.ygyno.2020.09.013_bb0135","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1200\/JCO.2008.19.7681","article-title":"Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies","volume":"27","author":"Kummar","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.013_bb0140","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/cncr.32600","article-title":"Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models","volume":"126","author":"Santiago-O\u2019Farrill","year":"2020","journal-title":"Cancer."},{"key":"10.1016\/j.ygyno.2020.09.013_bb0145","doi-asserted-by":"crossref","first-page":"43356","DOI":"10.18632\/oncotarget.17445","article-title":"The prognostic value of GLUT1 in cancers: a systematic review and meta-analysis","volume":"8","author":"Yu","year":"2017","journal-title":"Oncotarget."},{"key":"10.1016\/j.ygyno.2020.09.013_bb0150","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.3892\/ol.2016.5226","article-title":"PARP-1 may be involved in angiogenesis in epithelial ovarian cancer","volume":"12","author":"Wei","year":"2016","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ygyno.2020.09.013_bb0155","doi-asserted-by":"crossref","first-page":"8045","DOI":"10.1158\/0008-5472.CAN-10-2352","article-title":"Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment","volume":"70","author":"Chan","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2020.09.013_bb0160","doi-asserted-by":"crossref","first-page":"87638","DOI":"10.18632\/oncotarget.20936","article-title":"Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model","volume":"8","author":"Borst","year":"2017","journal-title":"Oncotarget."},{"key":"10.1016\/j.ygyno.2020.09.013_bb0165","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nature10155","article-title":"A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers","volume":"474","author":"Jirawatnotai","year":"2011","journal-title":"Nature."},{"key":"10.1016\/j.ygyno.2020.09.013_bb0170","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1111\/febs.12365","article-title":"MicroRNA-503 suppresses proliferation and cell-cycle progression of endometrioid endometrial cancer by negatively regulating cyclin D1","volume":"280","author":"Xu","year":"2013","journal-title":"FEBS J."},{"key":"10.1016\/j.ygyno.2020.09.013_bb0175","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ygyno.2018.10.027","article-title":"Cyclin D1 silencing impairs DNA double strand break repair, sensitizes BRCA1 wildtype ovarian cancer cells to olaparib","volume":"152","author":"Zhong","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.013_bb0180","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s10637-012-9922-7","article-title":"Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery","volume":"31","author":"Bundred","year":"2013","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.ygyno.2020.09.013_bb0185","doi-asserted-by":"crossref","first-page":"13837","DOI":"10.1038\/ncomms13837","article-title":"ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A","volume":"7","author":"Williamson","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ygyno.2020.09.013_bb0190","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/1535-7163.MCT-19-0019","article-title":"The novel ATR inhibitor BAY 1895344 is efficacious as Monotherapy and combined with DNA damage-inducing or repair-compromising therapies in preclinical cancer models","volume":"19","author":"Wengner","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ygyno.2020.09.013_bb0195","first-page":"479","article-title":"Combined treatment with PI3K inhibitor BKM120 and PARP inhibitor olaparib is effective in inhibiting the gastric cancer cells with ARID1A deficiency","volume":"40","author":"Yang","year":"2018","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ygyno.2020.09.013_bb0200","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/01.cad.0000173476.67239.3b","article-title":"PI3K\/Akt\/mTOR pathway as a target for cancer therapy","volume":"16","author":"Morgensztern","year":"2005","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.ygyno.2020.09.013_bb0205","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201911217","article-title":"Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors","volume":"12","author":"Lahiguera","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ygyno.2020.09.013_bb0210","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.celrep.2016.03.070","article-title":"PARP inhibition suppresses growth of EGFR-mutant cancers by targeting nuclear PKM2","volume":"15","author":"Li","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.ygyno.2020.09.013_bb0215","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/modpathol.3800656","article-title":"GLUT1 and GLUT8 in endometrium and endometrial adenocarcinoma","volume":"19","author":"Goldman","year":"2006","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2020.09.013_bb0220","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1002\/1097-0142(20000615)88:12<2774::AID-CNCR16>3.0.CO;2-I","article-title":"Immunohistochemical staining of GLUT1 in benign, hyperplastic, and malignant endometrial epithelia","volume":"88","author":"Wang","year":"2000","journal-title":"Cancer."},{"key":"10.1016\/j.ygyno.2020.09.013_bb0225","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in patients with newly diagnosed advanced ovarian Cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2020.09.013_bb0230","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"SOLO2\/ENGOT-Ov21 investigators, Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2020.09.013_bb0235","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1158\/1535-7163.MCT-17-1255","article-title":"Nuclear PTEN localization contributes to DNA damage response in endometrial adenocarcinoma and could have a diagnostic benefit for therapeutic Management of the Disease","volume":"17","author":"Mukherjee","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ygyno.2020.09.013_bb0240","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1038\/s41598-018-22289-7","article-title":"Loss of PTEN-assisted G2\/M checkpoint impedes homologous recombination repair and enhances radio-curability and PARP inhibitor treatment response in prostate cancer","volume":"8","author":"Mansour","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ygyno.2020.09.013_bb0245","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1101\/gad.14.1.34","article-title":"Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha","volume":"14","author":"Ravi","year":"2000","journal-title":"Genes Dev."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820339068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820339068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:53:53Z","timestamp":1758772433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825820339068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0090825820339068"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.09.013","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An olaparib window-of-opportunity trial in patients with early-stage endometrial carcinoma: POLEN study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}